Lofexidine is a prescription medicine indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. It is available as tablets for oral use. MedsAcross supplies Lofexidine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. Lofexidine tablets are a central alpha-2 adrenergic agonist indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.
Source: US FDA prescribing information
Lofexidine tablets are a central alpha-2 adrenergic agonist that binds to receptors on adrenergic neurons. This reduces the release of norepinephrine and decreases sympathetic tone.
Source: US FDA prescribing information
The usual Lofexidine tablets dosage is three 0.18 mg tablets taken orally 4 times daily at 5- to 6-hour intervals. Lofexidine tablets treatment may be continued for up to 14 days with dosing guided by symptoms. Discontinue Lofexidine tablets with a gradual dose reduction over 2 to 4 days. Hepatic or Renal Impairment: Dosage adjustments are recommended based on degree of impairment.
Source: US FDA prescribing information
None. None.
Source: US FDA prescribing information
Risk of Hypotension, Bradycardia, and Syncope: May cause a decrease in blood pressure, a decrease in pulse, and syncope. Monitor vital signs before dosing and advise patients on how to minimize the risk of these cardiovascular effects and manage symptoms, should they occur. Monitor symptoms related to bradycardia and orthostasis. When using in outpatients, ensure that patients are capable of self-monitoring for signs and symptoms. Avoid use in patients with severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal failure, as well as in patients with marked bradycardia. Risk of QT Prolongation: Lofexidine tablets prolong the QT interval. Avoid use in patients with congenital long QT syndrome.
Source: US FDA prescribing information
The following serious adverse reactions are described elsewhere in labeling: Hypotension, Bradycardia, and Syncope QT Prolongation Central Nervous System Depression Opioid Overdose Discontinuation Symptoms Most common adverse reactions (incidence ≥ 10% and notably more frequent than placebo) are orthostatic hypotension, bradycardia, hypotension, dizziness, somnolence, sedation, and dry mouth. or www.fda.gov/ medwatch
Source: US FDA prescribing information
Methadone: Methadone and Lofexidine tablets both prolong the QT interval. ECG monitoring is recommended when used concomitantly. Oral Naltrexone: Concomitant use may reduce efficacy of oral naltrexone. CYP2D6 Inhibitors: Concomitant use of paroxetine resulted in increased plasma levels of Lofexidine tablets. Monitor for symptoms of orthostasis and bradycardia with concomitant use of a CYP2D6 inhibitor.
Source: US FDA prescribing information
Storage Store in original container at controlled room temperature, 25°C (77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Lofexidine, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Lofexidine 0.18 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lofexidine 0.2 mg tabletOralGeneric name | — | US FDA | Available on request |
| Lucemyra 0.2 mg tabletOral | BioCorRx Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 16 May 2018 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Lofexidine and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Lofexidine, including Lucemyra.
Yes. The US FDA first approved Lofexidine on 16 May 2018, according to Drugs@FDA.
No listed presentation of Lofexidine is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Lofexidine is classified under ATC code N07BC04 (Lofexidine).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.